blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3740218

EP3740218 - COMBINATION THERAPY FOR TREATING OR PREVENTING CANCER [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  22.08.2024
Database last updated on 02.09.2024
FormerExamination is in progress
Status updated on  07.05.2021
FormerRequest for examination was made
Status updated on  23.10.2020
FormerThe international publication has been made
Status updated on  27.07.2019
Formerunknown
Status updated on  07.02.2019
Most recent event   Tooltip22.08.2024Application deemed to be withdrawnpublished on 25.09.2024 [2024/39]
Applicant(s)For all designated states
CJ Bioscience, Inc.
7F, B, 14, Sejong-daero
Jung-gu
Seoul 04527 / KR
[2023/49]
Former [2020/48]For all designated states
4D Pharma Research Limited
Life Sciences Innovation Building
Cornhill Road
Aberdeen, Aberdeenshire AB25 2ZS / GB
Inventor(s)01 / STEVENSON, Alexander
c/o 4D Pharma PLC 9 Bond Court
Leeds, West Yorkshire LS1 2JZ / GB
 [2020/48]
Representative(s)Reddie & Grose LLP, et al
The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
[N/P]
Former [2020/48]Marshall, Cameron John
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date19701725.418.01.2019
[2020/48]
WO2019GB50141
Priority number, dateGB2018000092719.01.2018         Original published format: GB 201800927
GB2018000150230.01.2018         Original published format: GB 201801502
GB2018000594110.04.2018         Original published format: GB 201805941
GB2018000657223.04.2018         Original published format: GB 201806572
GB2018000862825.05.2018         Original published format: GB 201808628
[2020/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019141996
Date:25.07.2019
Language:EN
[2019/30]
Type: A1 Application with search report 
No.:EP3740218
Date:25.11.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 25.07.2019 takes the place of the publication of the European patent application.
[2020/48]
Search report(s)International search report - published on:EP25.07.2019
ClassificationIPC:A61K35/74, A61K39/395, A61P35/00
[2020/48]
CPC:
A61K35/74 (EP,IL); A61K35/744 (KR,US); A61K31/337 (US);
A61K39/3955 (EP,IL,KR,US); A61K9/0019 (US); A61K9/0053 (US);
A61P35/00 (EP,IL,KR,US); C07K16/2818 (EP,IL,KR); A61K2039/505 (EP,IL,KR);
A61K2039/507 (EP,IL,KR); A61K2039/545 (US); A61K2300/00 (IL,KR);
C07K2317/76 (EP,IL,KR) (-)
C-Set:
A61K39/3955, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/48]
Extension statesBA13.08.2020
ME13.08.2020
Validation statesKH13.08.2020
MA13.08.2020
MD13.08.2020
TN13.08.2020
TitleGerman:KOMBINATIONSTHERAPIE ZUR BEHANDLUNG ODER VORBEUGUNG VON KREBS[2020/48]
English:COMBINATION THERAPY FOR TREATING OR PREVENTING CANCER[2020/48]
French:POLYTHÉRAPIE POUR LE TRAITEMENT OU LA PRÉVENTION DU CANCER[2020/48]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase13.08.2020National basic fee paid 
13.08.2020Designation fee(s) paid 
13.08.2020Examination fee paid 
Examination procedure13.08.2020Amendment by applicant (claims and/or description)
13.08.2020Examination requested  [2020/48]
13.08.2020Date on which the examining division has become responsible
06.05.2021Despatch of a communication from the examining division (Time limit: M06)
16.11.2021Reply to a communication from the examining division
18.02.2022Despatch of a communication from the examining division (Time limit: M06)
30.11.2022Reply to a communication from the examining division
08.02.2023Despatch of a communication from the examining division (Time limit: M06)
03.05.2024Application deemed to be withdrawn, date of legal effect  [2024/39]
27.05.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2024/39]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
30.11.2022Request for further processing filed
30.11.2022Full payment received (date of receipt of payment)
Request granted
08.12.2022Decision despatched
Fees paidRenewal fee
13.08.2020Renewal fee patent year 03
17.12.2021Renewal fee patent year 04
29.05.2023Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.01.202305   M06   Fee paid on   29.05.2023
31.01.202406   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Stay/Interruption17.03.2023Interruption of proceedings. Reason: legal prevention of applicant[2023/30]
02.11.2023Resumption of proceedings[2023/32]
17.03.2023Interruption of proceedings. Reason: legal prevention of applicant[2023/32]
Cited inInternational search[Y]US2016354416  (GAJEWSKI THOMAS F [US], et al) [Y] 1-24* the whole document *;
 [XDY]WO2017085520  (4D PHARMA RES LTD [GB]) [XD] 1-5,7-13,19-24 * the whole document * * claims 1-25 * * page 13, line 30 - page 16, line 22 * * page 14, line 1 * [Y] 1-24;
 [XPY]WO2018215782  (4D PHARMA RES LTD [GB]) [XP] 1-4,7-11,13,19-24 * the whole document * * claims 1-19 * * page 11, line 24 * [Y] 1-24;
 [XPY]  - Anonymous, "Archive History for NCT03637803", (20180816), URL: https://clinicaltrials.gov/ct2/history/NCT03637803?V_1=View#StudyPageTop, (20190221), XP055559945 [XP] 1-24 * the whole document * [Y] 1-24
 [Y]  - ARTHUR E. FRANKEL ET AL, "Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients", NEOPLASIA, US, (20171001), vol. 19, no. 10, doi:10.1016/j.neo.2017.08.004, ISSN 1476-5586, pages 848 - 855, XP055540712 [Y] 1-24 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.neo.2017.08.004
 [Y]  - BASHIARDES STAVROS ET AL, "The microbiome in anti-cancer therapy", SEMINARS IN IMMUNOLOGY, (2017), vol. 32, doi:10.1016/J.SMIM.2017.04.001, ISSN 1044-5323, pages 74 - 81, XP085246126 [Y] 1-24 * the whole document * * pages 77-78, paragraph 2.3 *

DOI:   http://dx.doi.org/10.1016/j.smim.2017.04.001
 [Y]  - BRANCH E, "The microbiome effect: Link found between immunotherapy success and gut Flora", AMERICAN PHARMACEUTICAL REVIEW, RUSSELL PUBLISHING, US, (20170101), vol. 20, no. 4, ISSN 1099-8012, pages 73 - 75, XP009511455 [Y] 1-24 * the whole document *
 [Y]  - ANONYMOUS, "The Gut Microbiome", REPORT ZEUS CAPITAL, ZEUS LONDON OFFICE, GB, (20170307), pages 1 - 34, URL: http://www.directorstalkinterviews.com/wp-content/uploads/2017/03/Microbiome-07032017.pdf, XP009511458 [Y] 1-24 * the whole document *
 [T]  - DELPHINE L. LAUTÉ-CALY ET AL, "The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant", SCIENTIFIC REPORTS, (20190128), vol. 9, no. 1, doi:10.1038/s41598-018-36926-8, XP055560064 [T] 1-24

DOI:   http://dx.doi.org/10.1038/s41598-018-36926-8
by applicantWO03046580
 WO2013008039
 WO2013050792
 WO2014167338
 US2016067188
 WO2017085520
    - SPOR et al., Nat Rev Microbiol., (20110000), vol. 9, no. 4, pages 279 - 90
    - ECKBURG et al., Science, (20050000), vol. 308, no. 5728, pages 1635 - 8
    - MACPHERSON et al., Microbes Infect, (20010000), vol. 3, no. 12, pages 1021 - 35
    - MACPHERSON et al., Cell Mol Life Sci, (20020000), vol. 59, no. 12, pages 2088 - 96
    - MAZMANIAN et al., Cell, (20050000), vol. 122, no. 1, pages 107 - 18
    - FRANK et al., PNAS, (20070000), vol. 104, no. 34, pages 13780 - 5
    - SCANLAN et al., J Clin Microbiol., (20060000), vol. 44, no. 11, pages 3980 - 8
    - KANG et al., Inflamm Bowel Dis., (20100000), vol. 16, no. 12, pages 2034 - 42
    - MACHIELS et al., Gut, (20130000), vol. 63, no. 8, pages 1275 - 83
    - GOLDIN; GORBACH, Clin Infect Dis., (20080000), vol. 46, no. 2, pages S96 - 100
    - AZAD et al., BMJ, (20130000), vol. 347, page f6471
    - STRICKERTSSON et al., Genes, (20140000), vol. 5, no. 3, pages 726 - 738
    - COLLINS et al., IntJSystEvol Microbiol., (19840000), vol. 34, pages 220 - 223
    - MASCO et al., Systematic and Applied Microbiology, (20030000), vol. 26, pages 557 - 563
    - SRUTKOVA et al., J. Microbiol. Methods, (20110000), vol. 87, no. 1, pages 10 - 6
    - HAABETH et al., OncoImmunology, (20120000), vol. 1, no. 1, pages 1146 - 1152
    - LEJEUNE et al., Cancer Immun., (20060000), vol. 6, page 6
    - PACE et al., PNAS, (19830000), vol. 80, pages 8782 - 6
    - SGADARI et al., PNAS, (19960000), vol. 93, pages 13791 - 6
    - ARENBERG et al., J. Exp. Med., (19960000), vol. 184, pages 981 - 92
    - SGADARI et al., Blood, (19970000), vol. 89, pages 2635 - 43
    - MIYAMOTO-SHINOHARA et al., J. Gen. Appl. Microbiol., (20080000), vol. 54, pages 9 - 24
    - Cryopreservation and Freeze-Drying Protocols, Humana Press
    - LESLIE et al., Appl. Environ. Microbiol., (19950000), vol. 61, pages 3592 - 3597
    - MITROPOULOU et al., JNutr Metab., (20130000), page 716861
    - KAILASAPATHY et al., Curr Issues Intest Microbiol., (20020000), vol. 3, no. 2, pages 39 - 48
    - STROBEL, Methods Mol Biol, (20090000), vol. 581, pages 247 - 61
    - Methods In Enzymology, Academic Press, Inc.
    - Handbook of Experimental Immunology, Blackwell Scientific Publications, (19860000), vol. I-IV
    - SMITH; WATERMAN, Adv. Appl. Math., (19810000), vol. 2, pages 482 - 489
    - ROCKWELL et al., JNatl Cancer Inst., (19720000), vol. 49, pages 735 - 49
    - BERTRAM; JANIK, Cancer Lett., (19800000), vol. 11, pages 63 - 73
    - DARLINGTON, Meth Enzymol, (19870000), vol. 151, pages 19 - 38
    - SIMPSON-HERREN; LLOYD, Cancer Chemother Rep., (19700000), vol. 54, pages 143 - 74
    - WORKMAN et al., Br. J. Cancer, (20100000), vol. 102, pages 1555 - 77
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.